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Abstract
Context—Diethylene glycol (DEG) mass poisoning is a persistent public health problem. 
Unfortunately, there are no human biological data on DEG and its suspected metabolites in 
poisoning. If present and associated with poisoning, the evidence for use of traditional therapies 
such as fomepizole and/or hemodialysis would be much stronger.
Objective—To characterize DEG and its metabolites in stored serum, urine, and cerebrospinal 
fluid (CSF) specimens obtained from human DEG poisoning victims enrolled in a 2006 case-
control study.
Methods—In the 2006 study, biological samples from persons enrolled in a case-control study 
(42 cases with new-onset, unexplained AKI and 140 age-, sex-, and admission date-matched 
controls without AKI) were collected and shipped to the Centers for Disease Control and 
Prevention (CDC) in Atlanta for various analyses and were then frozen in storage. For this study, 
when sufficient volume of the original specimen remained, the following analytes were 
quantitatively measured in serum, urine, and CSF: DEG, 2-hydroxyethoxyacetic acid (HEAA), 
diglycolic acid, ethylene glycol, glycolic acid, and oxalic acid. Analytes were measured using low 
resolution GC/MS, descriptive statistics calculated and case results compared with controls when 
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appropriate. Specimens were de-identified so previously collected demographic, exposure, and 
health data were not available. The Wilcoxon Rank Sum test (with exact p-values) and bivariable 
exact logistic regression were used in SAS v9.2 for data analysis.
Results—The following samples were analyzed: serum, 20 case, and 20 controls; urine, 11 case 
and 22 controls; and CSF, 11 samples from 10 cases and no controls. Diglycolic acid was detected 
in all case serum samples (median, 40.7 mcg/mL; range, 22.6 – 75.2) and no controls, and in all 
case urine samples (median, 28.7 mcg/mL; range, 14 – 118.4) and only five (23%) controls 
(median, <Lower Limit of Quantitation (LLQ); range, <LLQ–43.3 mcg/mL). Significant 
differences and associations were identified between case status and the following: 1) serum 
oxalic acid and serum HEAA (both OR = 14.6; 95% C I = 2.8 – 100.9); 2) serum diglycolic acid 
and urine diglycolic acid (both OR >999; exact p <0.0001); and 3) urinary glycolic acid (OR = 
0.057; 95% C I = 0.001–0.55). Two CSF sample results were excluded and two from the same 
case were averaged, yielding eight samples from eight cases. Diglycolic acid was detected in 
seven (88%) of case CSF samples (median, 2.03 mcg/mL; range, <LLQ, 7.47).
Discussion—Significantly elevated HEAA (serum) and diglycolic acid (serum and urine) 
concentrations were identified among cases, which is consistent with animal data. Low urinary 
glycolic acid concentrations in cases may have been due to concurrent AKI. Although serum 
glycolic concentrations among cases may have initially increased, further metabolism to oxalic 
acid may have occurred thereby explaining the similar glycolic acid concentrations in cases and 
controls. The increased serum oxalic acid concentration results in cases versus controls are 
consistent with this hypothesis.
Conclusion—Diglycolic acid is associated with human DEG poisoning and may be a biomarker 
for poisoning. These findings add to animal data suggesting a possible role for traditional antidotal 
therapies. The detection of HEAA and diglycolic acid in the CSF of cases suggests a possible 
association with signs and symptoms of DEG-associated neurotoxicity. Further work 
characterizing the pathophysiology of DEG-associated neurotoxicity and the role of traditional 
toxic alcohol therapies such as fomepizole and hemodialysis is needed.
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Introduction
Diethylene glycol (DEG) is a clear, colorless liquid used in the production of a wide variety 
of commercial and industrial products. 1 It is found in trace, non-harmful amounts in other 
products such as some dietary supplements and cosmetics (probably as a manufacturing 
contaminant). 2,3 When ingested in large amounts (1–1.5 g/kg), DEG can be a potent 
nephrotoxic and neurological poison. 1,4 Unfortunately, DEG’s physical and chemical 
properties give it similar properties to solvents safely used in drug delivery such as 
propylene glycol and glycerin. This fact, and its lower cost compared with solvents such as 
pharmaceutical grade glycerin have resulted in more than 13 medication-associated, DEG 
mass poisonings. These incidents were associated with more than 500 deaths and thousands 
of sub-lethal exposures around the world since 1937, many of which occurred in 
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children. 1,4–7 Many if not all appear to be the result of substitution for diluents such as 
propylene glycol and glycerin. 4,6–7 Despite the long history of medication-associated DEG 
poisoning, surprisingly little is known about the pathophysiology of human disease. As a 
result, the role of traditional antidotal therapy used in other, similar toxic alcohol poisonings 
(e.g., methanol and ethylene glycol) is unclear in DEG poisoning.
DEG is not hydrolyzed to two ethylene glycol molecules (animal data only) and further 
metabolized to known ethylene glycol metabolites, as once thought. 8 Limited animal and 
in-vitro evidence supports that DEG is metabolized to 2-hydroxyethoxy acetaldehyde by 
alcohol dehydrogenase (ADH) and then to 2-hydroxyethoxyacetic acid (HEAA) by aldehyde 
dehydrogenase. 8,9 (Figure 1) This work has also identified diglycolic acid as a DEG 
metabolite in animal poisoning experiments, 9,10 identified diglycolic acid as a substantial 
contributor to DEG induced acute kidney injury (AKI), 11,12 and shown that inhibition of 
DEG metabolism by an ADH inhibitor such as fomepizole (4-methylpyrazole) decreases 
kidney injury and lethality. 8,9 Unfortunately, there is no published information identifying 
the presence and/or pattern of HEAA and diglycolic acid concentrations in human DEG 
poisoning. Such information, if available, could be used to inform decision-making 
regarding whether or not to administer an agent such as fomepizole and/or perform 
hemodialysis. A single case report exists of a person who ingested a large amount of a pure 
form of one of these substances (diglycolic acid). He developed acute renal failure, 
peripheral neuropathy, coma, and ultimately died; unfortunately, no serum or urine 
toxicology testing was done. 13 The primary objective of this study was to identify and 
characterize DEG metabolite patterns in human serum, urine, and cerebrospinal fluid (CSF) 
specimens obtained from DEG poisoning victims. Our secondary objective was to compare 
these results to biologic specimens obtained from control-patients and describe the 
implications of these findings. This information may help clinicians characterize and 
quantify the severity and extent of human DEG poisoning by 1) identifying potential 
biomarkers for further validation; 2) informing laboratory assay development; 3) assisting 
clinicians in interpreting future biological testing results, and 4) provide data which can be 
used to inform future research and clinical decision-making.
Methods
Sample collection
All biological samples (serum, urine, and CSF) used in this study were obtained during an 
epidemiological investigation of a DEG mass poisoning in the Republic of Panama in 2006. 
This outbreak resulted when diethylene glycol was substituted for an appropriate diluent and 
used to formulate a sugarless cough syrup. 7 Biological samples from persons enrolled in a 
case-control study (42 cases with new-onset AKI and 140 age-, sex-, and admission date-
matched controls without AKI) were collected and shipped to the Centers for Disease 
Control and Prevention (CDC) in Atlanta for various analyses. Confirmatory laboratory 
testing for blood or urine DEG concentrations were not readily available during the actual 
outbreak and therefore could not be used in identifying cases for the case-control study. 
However, later testing by CDC on a sub-sample of urine specimens from the study revealed 
significantly higher urinary DEG concentrations in cases compared with controls. 7 Results 
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of the case-control study overwhelmingly implicated a locally produced cough syrup that 
was formulated with DEG. More detailed data on cases and controls are published 
(demographic, comorbidities, etc…) 7; however, descriptive information on actual exposure 
time and duration is limited. In the original outbreak, most exposures occurred one or more 
times daily, over several days. The samples analyzed for this project were collected during 
the 2006 case-control study. They were in general, collected several days after exposure 
began and at varying intervals for each case. 7 Appropriate public health measures were 
taken in response to these findings at the time. 7 The Panamanian biological samples were 
then stored at −70°C until internal funding to support this project became available. For this 
study, we analyzed biological samples that had sufficient volume remaining for the analysis 
from the original samples obtained from the 42 cases and 140 controls back in 2006. These 
included 20 case serum (48%) and 11 case urine (28%) specimens along with 20 control 
serum (14%) and 22 control urine (16%) specimens. Eleven case CSF samples representing 
10 patients that had neurological signs and symptoms were identified among the stored 
samples and analyzed. No control patient CSF samples were available for analysis. A single 
CSF specimen made from pooled CSF from 30 to 40 donors originally used for the matrix 
blank was also tested for all analytes.
Laboratory analysis
Samples were shipped frozen, on dry ice from the CDC to Dow Chemical Company for 
analysis due to their previous work analyzing animal biologic specimens for DEG and its 
metabolites. 9 The following analytes were measured in serum, urine, and CSF: DEG, 
ethylene glycol, glycolic acid, oxalic acid, HEAA, and diglycolic acid. Diglycolic acid and 
HEAA were chosen because they were either detected or suspected as possible metabolites 
in animal models of DEG poisoning. 8 Concentrations of ethylene glycol and its metabolites 
(glycolic and oxalic acid) were studied because of the unlikely, but theoretical, possibility of 
DEG metabolism to ethylene glycol in humans. These analytes were primarily chosen 
because of previous work that had resulted in analytical methods already developed to detect 
them in rat studies, which could be readily adapted to human samples. 9 The analyte 1,4-
dioxanone, a hypothesized molecule that may originate from HEAA only when analytical 
preparations involve strong acidification, was not included for this reason. 8
Sample analysis was conducted using chemical derivatization with gas chromatography 
(GC) using electron impact ionization or methane negative chemical ionization (NCI) with 
mass spectrometry (MS) detection (GC/EI/MS or GC/NCI/MS) for DEG and ethylene 
glycol and the four acid metabolites (glycolic acid, oxalic acid, HEAA, and diglycolic acid), 
respectively. The GC/MS methods were modifications of our previously reported techniques 
for ethylene glycol, glycolic acid, and oxalic acid. 14 Stable isotope-labeled analogs of each 
analyte were employed as quantitative internal standards in the assays. All analyses were 
performed on a Phenomenex (Torrance, CA, USA) ZB-5ms column (30 m X 0.25 mm I.D. 
×0.50 μm film). Helium carrier gas was used in constant flow mode. The following ions 
were used for quantitation with the MS operated in the SIM mode: GA, m/z 247.1; 13C-GA, 
m/z 248.2; HEAA, m/z 291.2; D6-HEAA, m/z 297.2, OA, m/z 261.1; 13C2-OA, m/z 263.1, 
DGA, m/z 305.2; D4-DGA, m/z 309.2 with dwell time of 100 ms for all ions and internal 
standards. Additional confirmation ions were not incorporated into the assay, due to the lack 
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of significant, compound-specific fragment ions and based on the extremely low 
concentrations of metabolites (EG, GA, OA, HEAA, and DGA) present in human samples. 
The use of stable-isotope labeled internal standards, however, confirmed analytes’ retention 
times for each sample analyzed. Also, the retention time and mass spectral response for each 
analyte was as a chemical derivative, providing further specificity to these analyses.
All matrices purchased for preparation of matrix standards were pooled from male and 
female donors who gave informed consent and were de-identified. Sample preparation for 
DEG and ethylene glycol by GC/MS in human samples was performed by adding urine, 
serum, or CSF sample aliquots to Milli-Q water. An aliquot of internal standard solution was 
added to each sample, followed by 5 N NaOH, toluene, and pentafluorobenzoyl chloride. 
The sample was vortex-mixed and heated 50°C for 1 h, and then centrifuged at 3400 rpm for 
10 min. The toluene layer was removed and analyzed by GC/NCI/MS.
Sample preparation for acid metabolites by GC/MS in human samples was performed by 
adding serum samples to acetonitrile at a 1:1 ratio in a centrifuge tube to precipitate proteins; 
the sample was briefly vortex-mixed followed by centrifugation at 15000 rcf for 10 min. An 
aliquot of urine, CSF or serum supernatant + 1 N HCl, was added to glass vial and capped. 
Internal standard solution was added followed by methyl-tert butyl ether (MTBE) containing 
0.5% trioctylphosphine oxide. Each sample was vortex-mixed for 30 min and the MTBE 
layer was transferred to a clean 2-mL glass auto sampler vial, the extraction step was 
repeated and the extracts were combined. Samples were blown to dryness under a nitrogen 
steam and then reconstituted in toluene and N-(tert.-Butyldimethylsilyl)-N-
methyltrifluoroacetamide derivatization reagent was added. Each vial was capped with a 
Teflon-lined crimp cap, heated at 60°C for 1 h, and then analyzed by GC/EI/MS.
Data analysis
Detection frequencies and descriptive statistics (median and range) were calculated. For 
observations in which the quantitative result was less than the lower limit of quantitation 
(LLQ), the LLQ divided by the square root of two was used instead in order to determine 
median concentration (serum, urine, and CSF). This was only done to determine median 
concentration for analytes that had more than 50% of their values above the LLQ. Analyte 
concentrations less than the LLQ were considered non-detectable and results analyzed by 
exact bivariable logistic regression (SAS v9.2) to determine the association of detection with 
case status. Analytes not significantly associated with case status by this method, but which 
had detectable concentrations in at least 90% of cases and 90% of controls, were 
dichotomized at the median and re-analyzed by exact logistic regression. The Wilcoxon 
Rank Sum test (with exact p-values) was also used to analyze the serum and urine results.
Simple quantitative descriptive statistics (median, range) were used to characterize CSF 
analyte concentrations. Two CSF samples were from a single subject; those values were 
averaged to produce a single result for analysis. Two samples were excluded from the 
analysis because we could not confirm that one originated from a case patient and one was 
from a case excluded from the original study. This left eight values, representing eight 
patients. All samples in the analysis originated from cases with neurological findings (e.g., 
flaccid paralysis, extremity weakness, facial palsy, etc.) previously associated with DEG 
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poisoning. 15 For comparison purposes, analyte testing results on the single CSF sample 
used as a matrix blank, which consisted of CSF from a pool of 30–40 persons obtained from 
a commercial bio-bank, is presented.
Although descriptive data were available for the 2006 study participants, informed consent 
for this investigation could not be obtained for a variety of reasons including subject loss to 
follow-up, deaths and difficulty in contacting patients from another country. Therefore all 
biological specimens were de-identified. The CDC Institutional Review Board determined 
this protocol to be exempt from review. The Dow Chemical Company’s Human Subjects 
Research Board approved the protocol.
Results
Twenty serum specimens from both cases and controls were analyzed. Eleven and 22 urine 
specimens were analyzed from cases and controls, respectively. Urinary oxalic acid 
concentration could not be determined because of strong matrix effects encountered during 
laboratory analysis. One case had insufficient quantities of urine to perform testing for 
glycolic acid, HEAA, and diglycolic acid and was excluded from the analysis.
Diglycolic acid was detected in all case serum and urine samples. Diglycolic acid was not 
detected in any control serum samples but was detected in five (22.7%) control urine 
samples (Table 1). The median case serum diglycolic acid concentration was 40.7 mcg/mL 
and the median case urine diglycolic acid concentration was 28.7 mcg/mL. In controls, the 
median value for each was less than the lower limit of quantitation. The median and ranges 
for all analytes in serum and urine in cases and controls are presented in Table 2.
When considered dichotomously (detected or non-detected), the presence of diglycolic acid 
was the only analyte significantly associated with case status (serum and urine, OR=>999; 
exact p < 0.0001) (Table 1). Some analytes (serum oxalic acid, glycolic acid, and HEAA 
along with urinary glycolic acid) had sufficient numbers (>90%) of samples with 
quantifiable concentrations in both cases and controls to analyze by exact logistic regression 
when dichotomized at the median into a “high” and “low” group. This demonstrated that 
elevated serum oxalic acid and serum HEAA concentrations were also significantly 
associated with case status (OR = 14.6; 95% CI= [2.8,101], for both analytes). Urinary 
glycolic acid concentrations were significantly lower among cases when compared with 
controls (OR=0.057; 95% CI=[0.001,0.546]). The Wilcoxon Rank Sum test gave similar 
results to the above-mentioned logistic regression analyses for serum (oxalic acid, HEAA, 
and diglycolic acid being higher in cases vs. controls) and urine (glycolic acid and diglycolic 
acid being lower and higher in cases vs. controls, respectively) (exact p<0.0001).
For the CSF samples (n=8), detection frequencies were as follows: DEG (n= 3; 38%), 
ethylene glycol (n=0), glycolic acid (n=8; 100%), HEAA (n=5; 63%), and diglycolic acid 
(n= 7; 88%). Median concentrations and ranges for all analytes in mcg/mL were as follows: 
DEG (<LLQ; range, <LLQ–4.82), glycolic acid (2.84; range, 1.77–3.77), HEAA (1.01; 
range, <LLQ–121), and diglycolic acid (2.03; range, < LLQ-7.47). The sole CSF specimen 
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used to develop the matrix blank had non-detectable concentrations for each analyte except 
for glycolic acid (2.91 μg/mL).
Discussion
Diglycolic acid and HEAA were identified in human DEG poisoning among not just one 
biological matrix, but three (serum, urine, and CSF). The strong association of diglycolic 
acid (serum and urine) and HEAA (serum only) with case status strongly suggests DEG as 
the etiology. The most striking results are the marked differences in serum and urine 
diglycolic acid concentration between cases and controls. It is interesting to briefly compare 
these results to those reported in DEG poisoned rats by oral gavage. The median diglycolic 
acid serum concentration of 41 μg/mL is approximately 0.3 mmol/L, which is much higher 
than concentrations reported in high-dose (10 g/kg) exposed rats (mean, 0.04 mmol/L; 
range, <LLQ, 0.2 mmol/L).10 This might be due to a different exposure scenario from the 
single, acute ingestion model used in these rat studies. In the original Panama mass 
poisoning, patients had been instructed to consume a dose of the implicated cough syrup 
containing DEG as much as three times a day for as long as needed. The kinetic data in rats 
also showed that diglycolic acid concentrations peaked at a later time than HEAA in serum. 
This might explain the high serum and urine diglycolic acid concentrations seen in our 
human cases relative to other analytes, since biological samples from cases were collected 
well after onset of illness. 7 Other animal and in-vitro work in cultured human kidney cells 
implicate diglycolic acid as a nephrotoxic agent in DEG poisoning. 11,12 The in-vitro work 
suggests that HEAA is not nephrotoxic. 11 Diglycolic acid appears to be the most likely 
etiology of DEG’s nephrotoxicity. 11,12
A previous study did not detect urinary diglycolic acid in a rat model of DEG poisoning. 8 
The authors hypothesized that HEAA might have formed a cyclic compound, 1,4-
dioxanone, not subject to further degradation. However, they used DEG doses of 1.1 g/kg 
which may have been too small to produce substantial diglycolic acid concentrations. 8 
Similar rat models have found detectable urinary diglycolic acid concentrations following 
higher DEG doses, from 2 to 10 g/kg. 10 Furthermore, the analytical methods used by 
Weiner et al. (high-performance liquid chromatography) 8 may have been unable to detect 
very small amounts of diglycolic acid, even if present, as compared with the GC/MS method 
used in later work. 10 Rat studies with dioxane suggest that HEAA and 1,4-dioxanone may 
co-exist in a pH-dependent equilibrium that is heavily favored toward HEAA, 16 although 
1,4-dioxanone may be favored in very acidic environments (<pH 5). 16–18 However, such a 
pH is not encountered even in the urine of rats with severe acidosis from high doses of 
DEG 9 and this compound is not observed under normal aqueous conditions in vivo. 16
Case serum and urine DEG concentrations were not significantly higher than controls. This 
is not surprising given that biological samples were typically collected days after last 
exposure to the cough syrup, allowing sufficient time for DEG metabolism (half-life of 5–13 
h). 5,7,10 The few control samples that did have detectable serum DEG concentrations may 
have resulted from background environmental exposures as DEG can be found in packaging 
materials, cosmetics, and certain foodstuffs such as dietary supplements. 2,3 During the 
initial outbreak investigation in 2006, urinary DEG concentrations were determined by CDC 
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on a small sample of case and control-patient specimens: a significant difference was 
found. 7 The reason for the difference in findings between the 2006 study and this one may 
be due to different samples being tested although the possibility that DEG underwent some 
degradation while in storage is possible.
Case serum samples had significantly higher HEAA concentrations compared with controls 
as expected given that HEAA is a known metabolite of DEG. A possible explanation for the 
fact that many control samples had low but detectable serum HEAA concentrations is 
background environmental exposure. This may have occurred from personal care products 
containing either DEG as noted above or 1,4-dioxane which is metabolized to HEAA in 
vivo. 19,20 Three samples (one case serum, one case urine, and one control urine sample) 
contained detectable ethylene glycol concentrations. This may be due to background 
environmental exposure among controls or possibly from further reaction of one of the DEG 
acid or aldehyde intermediates 10 (not by DEG metabolism to two ethylene glycol 
molecules). Finally, although control patients in the study had to have been hospitalized for 
any condition besides AKI, 7 they could have received the implicated DEG-containing 
cough syrup while in the hospital. The implicated medication was formulated in a 
pharmaceutical manufacturing plant operated by the hospital system and distributed to 
patients of this system. This might also explain why a few control-patients had detectable 
concentrations of DEG and HEAA.
Urinary glycolic acid concentrations were significantly lower among case samples when 
compared with controls. Limited human data suggest that normal urinary glycolic acid 
concentrations are approximately 38.8 mg/day (SD: 13.8 mg) and depend largely on diet. 21 
If one assumes an average adult urine volume of 1.5 L, control patients were probably 
excreting similar amounts, approximately 22.5 mg/day (15 mcg/mL× 1500 mL/day) of 
glycolate. These values are proportionally much greater than the median urinary glycolic 
acid concentrations seen among cases (3 mcg/mL × 1500 mL/day or 4.5 mg/day). The lower 
values among cases may be due to an impaired ability to excrete glycolic acid due to AKI 
from DEG’s nephrotoxic effects. Impaired kidney function in cases may have reduced 
elimination of glycolic acid in urine, resulting in the availability of serum glycolic acid for 
further metabolism. As glycolic acid was present in the serum due to AKI, it may have been 
metabolized to oxalic acid (as well as other unmeasured organic acids) via normal metabolic 
pathways 22 and oxalate accumulated in the serum of the cases due to impaired kidney 
function. Additionally, late sample collection relative to exposure may have resulted in 
simply missing the peak serum glycolic acid concentration. Unfortunately, our samples did 
not capture serial measurements over time and alternative explanations for these findings 
may exist. As expected, almost all cases and controls did not have detectable serum and 
urine ethylene glycol concentrations.
The pathophysiology of DEG-induced neurotoxicity is much less clear and unstudied. The 
detection of HEAA and diglycolic acid in nearly all case CSF samples suggests that these 
metabolites may be associated with DEG-associated neurotoxicity. Signs and symptoms of 
non-inebriation related neurotoxicity tend to only appear following nephrotoxicity, 1 hence 
these findings make intuitive sense (the nephrotoxic agents seem likely to also be the 
neurotoxic agents). Unfortunately, the data and the study design were insufficient to 
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adequately characterize this issue and make a determination on causation. True control CSF 
samples with undetectable concentrations of DEG metabolites would have enabled us to say 
more; alas none were available for testing. Nevertheless, the single bio-bank supplied CSF 
sample had no detectable HEAA or diglycolic acid concentrations providing at least one 
comparison value. The finding of glycolic acid in the bio-bank CSF sample is not 
unexpected since it is an endogenous metabolic intermediate that is likely present at some 
small level in all body fluids.
Taken together, these findings suggest that the DEG metabolites diglycolic acid and HEAA 
are associated with human DEG poisoning: these results appear similar to those found in 
animal models of DEG poisoning. Although this study did not assess causation, these data 
provide further insight into the metabolism of DEG in humans after poisoning and more data 
to inform future work in studying potential DEG poisoning therapies. Although the role of 
HEAA and diglycolic acid in DEG-associated neurotoxicity remains unclear, the limited 
CSF findings from this study suggest a possible association. The possibility that other 
unmeasured analytes may occur following DEG poisoning exists as well and these may also 
contribute to poisoning.
Limitations
The initial outbreak study was a case-control study that employed a matched study design. 
Due to the need for subject de-identification, we could not perform a matched, multivariable 
analysis. The true association between diglycolic acid and case status may be stronger than 
what we found, since ignoring the matching in the analysis of matched data typically biases 
results toward the null. 23 Another limitation is that the time interval between last dose and 
biological sample collection is unknown for each case. This probably resulted in substantial 
variation between analyte concentrations among cases, which limits the utility in using the 
quantitative data to examine dose-response relationships. We also did not measure 1,4-
dioxanone concentrations due to the unlikeliness of its presence at the urine and blood pH 
that are encountered in human DEG poisoning; such measurements would have further 
supported that this compound is not formed in appreciable amounts in vivo (consistent with 
rat studies). 16 Nor did we measure dioxane which can be metabolized to HEAA and might 
have affected HEAA measurements and their interpretation. It is likely that many of the 
cases were receiving hemodialysis during their clinical course. This may have affected 
analyte concentrations and quantitative measurements should be interpreted with this 
possibility in mind. Finally, the quantitative methods used for the laboratory analysis lacked 
the necessary specificity to exclude with complete certainty all other substances that have 
the same retention time and mass spectra on the low resolution GC/MS methods used. 
Further refinement of these methods to include detection of two confirmatory ions, in 
addition to the primary ion of interest, is needed to completely eliminate any other 
possibility. Nevertheless, we believe the likelihood of an alternative substance mimicking 
any of these analytes on GC/MS is extremely low based on several factors. The use of 
stable-isotope labeled internal standards confirmed analytes’ retention times for each sample 
analyzed. Limited analyses of the CSF samples by a complementary ion chromatography–
mass spectrometry method, used on previous animal studies with DEG, afforded comparable 
results to the GC/MS data presented here (data not shown). Additionally, most of the 
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measured metabolite concentrations are consistent with previously published animal DEG 
pharmacokinetic data.
Conclusion
Diglycolic acid (serum and urine) and HEAA (serum) concentrations are identifiable in, and 
associated with, human DEG poisoning. Diglycolic acid and perhaps HEAA appear to be 
useful biomarkers for human DEG poisoning but require further validation. These results 
may also be useful in interpreting biological testing results in future instances of DEG-
associated illness. Further work characterizing the role of ADH inhibiting therapies such as 
fomepizole and ethanol, as well as hemodialysis, in treating DEG poisoning is needed. 
Finally, more work in human specimens is needed to validate these findings and to elucidate 
the role of HEAA and diglycolic acid in DEG-associated neurotoxicity.
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Metabolic pathway for DEG based on previous animal studies and on the results presented 
in this report. Metabolites in lined boxes have been observed following administration of 
DEG to animals; those in dashed boxes are theoretical intermediates. Because fomepizole 
reduced the amount of EG in the urine, its origin is shown as coming from the aldehyde or 
acid intermediate, rather than from DEG itself. ALDH, aldehyde dehydrogenase. DGA is 
also known as oxybisacetic acid. Reprinted with permission from Reference # 9: Besenhofer 
LM, Adegboyega PA, Bartels M, et al. Inhibition of metabolism of DEG prevents target 
organ toxicity in rats. Toxicol Sci 2010;117(1):25–35.
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